Mediar Therapeutics
- Biotech or pharma, therapeutic R&D
Mediar is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar currently has three novel first in class programs that are at various stages of development:
- WISP1 (MTX-463): Running a Phase 2 Idiopathic Pulmonary Fibrosis (IPF) & partnering with Lilly.
- EphrinB2 (MTX-474): Phase 1 complete, starting Phase 2 systemic sclerosis (SSc) study in H2-2025.
- SMOC2: Target for kidney fibrosis in lead optimization; clinical candidate expected in H2-2025.
Mediar has a strong discovery-to-clinic track record and is evaluating R&D partnerships on SMOC2 and more broadly on other fibrosis targets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}